These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 16481098

  • 1. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z.
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract] [Full Text] [Related]

  • 2. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R, de Argumedo GL, Mañé JM, Muñoz A, Ferreiro J, Fuente N, López-Vivanco G.
    J Clin Oncol; 2005 Sep 20; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract] [Full Text] [Related]

  • 3. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA, Wood CG.
    Hematol Oncol Clin North Am; 2011 Aug 20; 25(4):753-64. PubMed ID: 21763966
    [Abstract] [Full Text] [Related]

  • 4. Presurgical therapy in metastatic renal cell carcinoma.
    Jonasch E.
    Expert Rev Anticancer Ther; 2007 Jan 20; 7(1):73-8. PubMed ID: 17187521
    [Abstract] [Full Text] [Related]

  • 5. Cytoreductive nephrectomy: past, present and future.
    Galazi M, Rodriguez-Vida A, Josephides E, Chau NM, Chowdhury S.
    Expert Rev Anticancer Ther; 2014 Mar 20; 14(3):271-7. PubMed ID: 24392671
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988.
    Yagoda A.
    Prog Clin Biol Res; 1990 Mar 20; 350():227-41. PubMed ID: 2201045
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
    Bex A, Powles T.
    Expert Rev Anticancer Ther; 2012 Jun 20; 12(6):787-97. PubMed ID: 22716495
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ, Gorbonos A, Milner JE, Flanigan RC.
    Int J Urol; 2009 Mar 20; 16(3):227-33. PubMed ID: 19207114
    [Abstract] [Full Text] [Related]

  • 15. Metastatic renal cell carcinoma: recent advances in the targeted therapy era.
    Di Lorenzo G, Autorino R, Sternberg CN.
    Eur Urol; 2009 Dec 20; 56(6):959-71. PubMed ID: 19748725
    [Abstract] [Full Text] [Related]

  • 16. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE, Figlin RA.
    Cancer; 2009 May 15; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.